Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19

Conditions: ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2, Acute Refractory Heart Failure Related to SARS-CoV 2

Sex: All

Healthy volunteers: No

Enrollment: 761

Sponsor: Rennes University Hospital

Summary

The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known. The present study will aim to report the results of the ECMO management of the most severe forms of COVID-19 through the first French ECMO registry.

Eligibility Criteria

Inclusion Criteria: * All COVID-19 patients, adults or children, * Tested positive by RT-PCR for SARS-CoV2 (nasopharyngeal swabs, sputum, endotracheal aspiration, bronchoalveolar lavage or stool sample) and / or with a diagnosis made on chest CT findings, * Supported by venovenous or venoarterial ECMO Exclusion Criteria: * Temporary legally protected Adults over a set period or waiting for protection supervision, guardianship * Patients or proxies who express their opposition to study participation

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04397588). StuddyBuddy aggregates publicly available trial information.